Meeting
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
Authors
Catherine Callaghan Coombs
University of North Carolina at Chapel Hill, Chapel Hill, NC
Catherine Callaghan Coombs , Nancy Gillis , Kelly L Bolton , Jonathan S. Berg , Xianming Tan , Michele C Hayward , Nirali M. Patel , Markus Ball , Maria Balasis , Tania MESA , Nathan Montgomery , Kristy L. Richards , William Y. Kim , David N. Hayes , Shelton Earp , Joel S. Parker , Ross L. Levine , Elli Papaemmanuil , Ahmet Zehir , Eric Padron
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12068)
DOI
10.1200/JCO.2018.36.15_suppl.12068
Abstract #
12068
Poster Bd #
181
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
First Author: Emmanuel S. Antonarakis
Poster
2019 ASCO Annual Meeting
Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.
First Author: Madison Conces
Poster
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
First Author: Catherine Handy Marshall
Poster
2023 ASCO Quality Care Symposium
CHIPping in: Clonal hematopoiesis clinics in community oncology.
First Author: Michael Byrne